Author: Dr. Sergey Terushkin, MD, FACS
Key Takeaways: The 30-Second Summary
🟢 Availability: Tirzepatide is FDA-approved and available at our clinic today. Retatrutide is in clinical trials and likely won’t be available until 2026 or 2027.
🟢 Effectiveness: Tirzepatide offers massive weight loss (up to 21%). Retatrutide shows slightly higher potential (~24%), but the difference is small compared to waiting years for treatment.
🟢 Safety: Tirzepatide has a proven safety profile. Retatrutide is still being studied for potential cardiac side effects (increased heart rate).
🟢 Access: We offer Telehealth appointments and flexible payment plans (including CareCredit) to make starting easy.
⭐ Your weight-loss journey starts here. Call (954) 551-3508 or submit the form — we’ll reach out when it’s best for you.
In the fast-moving world of medical weight loss, there is always a new headline grabbing attention. Currently, the buzz is surrounding Retatrutide, an experimental “triple-agonist” drug. While the early data is exciting, it is likely years away from being available to the public.
At Florida Surgery & Weight Loss Center, we focus on proven, safe, and available solutions right now.
The current gold standard—Tirzepatide (popularly known as Mounjaro® or Zepbound®)—is already changing lives in our clinic. Many patients ask if they should wait for the “new” drug. The answer is simple: Your health shouldn’t have to wait.
Both medications work by mimicking natural hormones that control hunger and metabolism, but there is a slight difference in their “engines.”
The Bottom Line: Retatrutide offers a modest increase in potential weight loss (approximately 3%), but it is still in clinical trials. Tirzepatide offers massive, life-changing results and is available to you today.
| Feature | Tirzepatide | Retatrutide |
|---|---|---|
| GLP-1 | ✔ | ✔ |
| GIP | ✔ | ✔ |
| Glucagon | ✘ | ✔ (unique advantage) |
| Fat-Loss Power | Very high | Highest in trials |
While both drugs are effective, adding a third hormone (Glucagon) in Retatrutide brings a different side effect profile that researchers are still studying.
1. Shared Side Effects (Both Drugs) Most GLP-1 medications share a similar profile as your body adjusts:
2. Unique Side Effects (Retatrutide vs. Tirzepatide)
| Feature | Tirzepatide (Available Now) | Retatrutide (Experimental) |
| Cardiac Impact | Minimal impact on heart rate. | Increased Heart Rate: Trials show a noticeable increase in resting heart rate. |
| Skin Sensitivity | Rare. | “Sunburn” Sensation: ~7% of patients reported skin tenderness (cutaneous hyperesthesia). |
| Safety Status | FDA-Approved: Safety profile is well-established. | Investigational: Long-term cardiac safety is still being studied. |
“Retatrutide represents a major medical breakthrough. Until FDA approval, our priority remains offering patients safe, effective, accessible weight-loss solutions that work today.”
Disclaimer: Dosage and pricing may vary based on medical evaluation. Please call us for more information.
You don’t need to navigate this journey alone. Led by Dr. Sergey Terushkin, a board-certified and fellowship-trained surgeon, our program is designed for convenience, affordability, and medical safety.
We understand your life is busy. You do not need to sit in a waiting room to get high-quality care.
We believe financial barriers shouldn’t stand between you and your health.
Ordering medication online from unknown sources is risky. At our center, you receive medical-grade Tirzepatide under the supervision of a top-rated surgeon. We monitor your body composition to ensure you are burning fat, not muscle.
• Sermorelin – Stimulates natural growth hormone production
• CJC-1295 – Enhances growth hormone release, supports fat loss & lean muscle gain
• Tesamorelin – Reduces visceral fat & supports metabolism
• BPC-157 – Accelerates healing of muscles, tendons & gut lining
• Ipamorelin – Improves sleep, recovery, and muscle development
• GLP-1 – Appetite control & weight management support as part of our medical weight loss program
Each program is personalized by Karla K. Mioduchoski, FNP-BC for your goals, with a focus on safety, affordability, and results.
A: No. Retatrutide is not FDA-approved and is only available in clinical trials. Tirzepatide is the most effective FDA-approved option available today.
A: Clinical trials suggest Retatrutide may work slightly faster due to its “triple” action, achieving ~24% weight loss in 48 weeks, compared to Tirzepatide’s ~21% in 72 weeks. However, since Retatrutide is not available yet, waiting for it actually delays your progress. Starting Tirzepatide now allows you to lose significant weight immediately.
A: Early data show Retatrutide is highly effective for blood sugar control and may clear liver fat better than current options. However, Mounjaro (Tirzepatide) is already FDA-approved and proven to lower A1C effectively. If you have Type 2 Diabetes, Mounjaro is the gold standard treatment available today
A: This is a key difference. In clinical trials, Retatrutide was associated with a greater increase in resting heart rate than Tirzepatide. This cardiac stress is one of the main reasons the drug is still in testing. Tirzepatide has a more established safety profile regarding heart health.
A: Great question. Typically, Glucagon raises blood sugar. However, in Retatrutide, it is combined with GLP-1 and GIP. In this specific combination, the Glucagon receptor increases energy expenditure (calorie burning) without spiking blood sugar. It turns up your metabolic “furnace.”
A: While pricing isn’t set, newer drugs often launch at a premium. Additionally, insurance coverage for new drugs typically lags by 6–12 months after approval. Many insurance plans already cover Tirzepatide for qualified patients, and we offer affordable self-pay options for those without coverage.
The content provided in this blog post is for informational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and not FDA-approved. Individual results with Tirzepatide may vary. Always consult Dr. Terushkin or a qualified provider before starting any weight loss program.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial
• Patient-friendly explanation of emerging weight-loss peptides
FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Real people, REAL RESULTS! Check out a few of the many people that we have helped reach their ideal weight goals over the years.
